Breaking AI & Tech News Analyzed

Executive Summary: AI Errors Could Trigger Negligence Lawsuits for CliniciansDoctors and the NHS may be held personally liable for patient harm caused by artificial‑intelligence tools used in diagnosis and treatment, according to a new report from the Medical Protection Society (MPS). Under current UK law, clinicians remain the accountable party even when an AI system makes the mistake.AI Integration in NHS Clinical PathwaysThe health service is expanding AI use across several functions, including:Automated analysis of scans and X‑raysGeneration of consultation summariesDrafting of patient lettersThese tools aim to speed decision‑making, but the MPS warns that rapid deployment outpaces existing legal safeguards.Legal Landscape: Current Liability FrameworkPresently, clinical negligence claims are directed at the treating clinician or the NHS Trust, not at the AI developer. The MPS argues that AI should be re‑classified as a “product” under the Consumer Protection Act 1987, which would bring manufacturers into the liability chain.Potential Consequences for Trust and PracticeDoctors could become a “liability sink” for AI‑related errors, discouraging adoption.Public confidence in NHS services may erode if accountability appears unclear.Legal costs and insurance premiums for clinicians could rise sharply.Examples cited include an AI missing a lung tumour on a chest X‑ray and an AI incorrectly recommending a higher dose of warfarin, both scenarios that could lead to fatal outcomes.Calls for Reform and Outlook for RegulationStakeholders—including the MPS, the Society for Acute Medicine, and the Health Foundation—are urging the Department of Health and Social Care to adopt the report’s recommendations. Draft guidelines from NHS Resolution are under review, and policymakers are being asked to align legislation with the speed of AI innovation to avoid an “accountability vacuum.”

MPs Challenge New Ministerial Power Over NHS Drug PricingThirty‑one MPs from Labour, the Greens, the Liberal Democrats, the SNP, Plaid Cymru and independents have signed a House of Commons motion opposing a statutory instrument that gives Wes Streeting the authority to tell the National Institute for Health and Care Excellence (NICE) which cost‑effectiveness threshold to apply when appraising new medicines.The opposition frames the change as a “power grab” that could erode the agency’s role as an international benchmark for value‑for‑money drug decisions.Numbers Behind the Opposition31 MPs have signed the motion.The statutory instrument was issued in 2026 as part of a broader UK‑US drug‑pricing deal.Health experts warn the deal could add billions of pounds to the NHS drug bill.Potential Consequences for NHS Funding and Drug RegulationCritics, including former health secretary Andrew Lansley, argue the new power may conflict with the Health and Social Care Act 2012, which protects NICE’s independence. If the threshold is lowered, pharmaceutical companies could secure higher prices, forcing the NHS to divert funds from other services such as surgeries or nursing staff.Think‑tanks like the Health Foundation warn that a larger drug spend will trigger “difficult cuts” to preventative and primary‑care programmes.What the Next Parliamentary Battles May HoldWith the motion tabled as a “prayer”—a formal way for MPs to register dissent on secondary legislation—the opposition could pressure the government to amend or repeal the instrument. John McDonnell and other senior Labour figures have signalled readiness to push for a full debate in the Commons, while the House of Lords may see a “motion of regret” from Lord Lansley.If the government persists, legal challenges could arise over the compatibility of the statutory instrument with existing health law, potentially leading to judicial review.